FDA Approved: AMBRISENTAN — Supplemental Application (Cipla USA Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ambrisentan from Cipla USA Inc., authorizing a supplemental approval under ANDA210715.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Ambrisentan (Ambrisentan)

Snippet

SUPPL AP for AMBRISENTAN (AMBRISENTAN)